The concept of regrowing teeth revolves around an antibody drug developed by Toregem Biopharma, a Kyoto University affiliated startup. Dr. Katsu Takahashi, a renowned researcher and oral surgeon based at Kitano Hospital in Osaka is at the forefront of this medical advancement. Their research is targeting the blocking of protein which enables the third set of teeth to awaken.
The drug targets a specific protein, known as uterine sensitization-associated gene-1 (USAG-1) which normally stops tooth growth. By deactivating this protein, scientist have triggered tooth regrowth. Research was successfully demonstrated in animals like mice and ferrets without serious side effects. The drug is administrated intravenously to prove its efficacy and safety. No side effects have been reported in previous animal studies and now advancing to human trials.
Clinical trials in 2024 focused on individuals with at least one missing molar. Further team targets to test to the drug in 2025 on children with congenital anodontia (born without six or more permanent teeth). If all goes according to plan, Toregem Biopharma aims to bring this revolutionary treatment to market by 2030. The company envisions the drug being offered at around 1.5 million yen (approx. $9800).
This could transform dental care, offering a more natural and less invasive alternate to current solutions like dentures and implants.
Substantial obstacles are there, especially ensuring teeth grow correctly, teeth erupts at right position in mouth, cost of therapy and drug’s efficacy across different age groups and conditions. Hopefully, scientist will see good results in coming months.
Conclusion
Till research and human trials are going on, maintain your teeth by brushing two times daily for two minutes, flossing once a day and dental visits twice a year. Consult Dr. Archan Mal for all your dental problems at Floss & Gloss Dental Clinic based in Shela, VIP road.